The last time a breakthrough in cardiac inflammation made waves, few investors were watching.
Then, Kiniksa’s drug got approved and it has amassed to over a $2 billion dollar market cap.
History may be about to repeat itself.
Another company is targeting the same painful condition. But this time, this next-generation therapy is oral. It’s non-immunosuppressive. And it’s currently enrolling patients in a Phase III trial for recurrent pericarditis after completing a highly successful Phase II trial last year.
Recurrent pericarditis is a brutal heart condition with only one FDA-approved drug that costs more than $270,000 a year and suppresses the immune system.
This is not a wellness trend. It’s not a hype cycle.
It’s a novel therapy for a billion-dollar problem the medical community desperately needs alternative treatments for.
And the analysts are waking up.
Two firms have already issued price targets that imply a 600% upside. Others are starting to follow.
Here’s a company no one is talking about—yet.
Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.
This message is a paid advertisement for Cardiol Therapeutics Inc. from Market Jar Media Inc. Wealthpire, Inc. receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $5,000. Other than the compensation received for this advertisement sent to subscribers, Wealthpire, Inc. and its principals are not affiliated with either Cardiol Therapeutics Inc. (CRDL) or Market Jar Media Inc. Wealthpire, Inc. and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither Wealthpire, Inc. nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Wealthpire, Inc. to buy or sell any security. Wealthpire, Inc. has not evaluated the accuracy of any claims made in this advertisement. Wealthpire, Inc. recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Cardiol Therapeutics Inc. (CRDL) on Market Jar Media Inc. website for additional information about the relationship between Market Jar Media Inc. and Cardiol Therapeutics Inc. (CRDL).
